Shots:

• Out of 5 approvals three are for NSCLC patients- one for Melanoma and one for Microsatellite Instability-High (MSI-H) solid tumor patients

• Keytruda got approved as monotherapy in 1L PD-L1 positive NSCLC patients based on Keynote-042- one in 1L non-squamous patients in combination with pemetrexed and PT-CT based on keynote-189 and another for 1L squamous NSCLC patients in combo with nab/paclitaxel+ carboplatin based on keynote-407 both regardless of PD-L1 expression

• Approval in melanoma as adjuvant monotherapy based on keynote-054 and approval in MSI-H solid tumor for 2L post companion diagnosis by Falco based on keynote-164- 158

Ref: Merck | Image: Merck